Cardiol Therapeutics Inc. CRDL PHARMA
Company Overview
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +100.00% |
| 6 Months: | +126.76% |
| 3 Months: | +105.56% |
| 1 Month: | +56.34% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)74.76 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRDL Cardiol Therapeutics Inc. PHARMA | 2.22 | -8.88 | $259.35M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 8.43M | 7.68M | 10.18M | 8.03M | 9.71M |
| Operating Income | - | -8.43M | -7.68M | -10.18M | -8.03M | -9.71M |
| EBITDA | - | -8.40M | -7.65M | -10.15M | -8.00M | -9.68M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -8.29M | -8.35M | -9.96M | -7.21M | -10.82M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -8.29M | -8.35M | -9.96M | -7.21M | -10.82M |
| Diluted EPS | - | -0.10 | -0.10 | -0.12 | - | -0.10 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 41.34M | 29.79M | 40.28M | 34.32M |
| Operating Income | - | -41.34M | -29.79M | -40.28M | -34.32M |
| EBITDA | - | -41.12M | -29.54M | -39.90M | -34.21M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -30.93M | -28.13M | -36.68M | -33.82M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -30.93M | -28.13M | -36.68M | -33.82M |
| Diluted EPS | - | -0.49 | -0.44 | -0.51 | -0.39 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 62.03M | 36.70M | 31.86M | 23.62M |
| Current Assets | - | 61.44M | 36.15M | 31.67M | 23.50M |
| Cash & Equivalents | - | 59.47M | 34.93M | 30.58M | 21.42M |
| Inventory | - | - | - | - | - |
| Receivables | - | 209.92K | 142.75K | 100.37K | 55.73K |
| Total Liabilities | - | 9.83M | 8.45M | 7.14M | 5.74M |
| Current Liabilities | - | 9.80M | 8.30M | 7.01M | 5.66M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 72.87K | 174.34K | 158.53K | 125.52K |
| Total Equity | - | 52.20M | 28.25M | 24.73M | 17.88M |
| Shares Outstanding | - | 64.04M | 65.35M | 82.61M | 100.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -27.22M | -25.18M | -25.06M | -23.85M |
| Investing Cash Flow | - | -74.71K | -64.31K | -21.29K | -24.48K |
| Financing Cash Flow | - | -53.93K | -55.38K | 18.84M | 15.54M |
| Capital Expenditure | - | -74.71K | -64.31K | -21.29K | -24.48K |
| Free Cash Flow | - | -27.30M | -25.24M | -25.08M | -23.88M |
| Net Change in Cash | - | -27.35M | -25.30M | -6.24M | -8.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -59.3% | -99.6% | -148.3% | -189.2% |
| ROCE % | - | -79.2% | -104.9% | -162.1% | -191.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | MMCAP International, Inc. SPC | 13.43% | 15.60M | $29.25M |
| 2 | Tejara Capital Ltd | 4.40% | 5.11M | $9.59M |
| 3 | Ikarian Capital, LLC | 2.86% | 3.33M | $6.23M |
| 4 | Boothbay Fund Management, LLC | 0.84% | 975.72K | $1.83M |
| 5 | Citadel Advisors Llc | 0.69% | 796.53K | $1.49M |
| 6 | Renaissance Technologies, LLC | 0.67% | 772.84K | $1.45M |
| 7 | Two Sigma Investments, LP | 0.64% | 746.94K | $1.40M |
| 8 | Integrity Alliance, Llc. | 0.33% | 388.49K | $728.42K |
| 9 | Morgan Stanley | 0.31% | 355.03K | $665.68K |
| 10 | Goldman Sachs Group Inc | 0.29% | 333.90K | $626.06K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRDL
CRDL Stock Price, Quote & Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5GbXg2UUFVY0pFRTBTTmNnTU9fcENFWjNkNFJIazJhT2hhRmdhR3g5Z1l5UDJVOTBpQWRNa2RiOThtaVlWYjRVR2ppMHJWRjBDWnJab3ROX05BUEVvN2Z3?oc=5" target="_blank">CRDL Stock Price, Quote & Chart</a>&nbs…
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNS3V3Y3dNUmZjRXJtSFFoYjlBbWJQZVNhR2diaXIxQzZjUldfVDJXYl9vSmtzZUFaa0todjZLemZ4cjVJZGRvYzVRMWxoRzhuNGQtTzVZYk9salNVU21xQjl5VlpvXy1PRVlEV0NXRWtnV2cwaXJ2SlZmUm53c3R3c1JiRGs1LTV2TlhTZU…
CRDL Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE9HVnNSamZ4Q012M1U1a21nMzRVaGJmNDhrTmU4bGRSbkh1UWVkRDZrRjJRTWMwLUVCal9jRm84YzRSX1FYVnZIQmdvRnlEck5GRkt5Y25fMmIxRGpkLTIxX0prekpOb0Z4Mml2dTlGWGRPeDZRRVE?oc=5" target="_blank">CRDL For…
MMCAP and MM Asset Management (CRDL) reveal 21.3M-share Cardiol Therapeutics stake - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOdE5ud1U3VUpEVkpydEZ4NktCWkkxS3FyQ0Nja2Qxd2UxcXdLcDg3VDNPODNQcHJqOU1jZU9pNnpvWmN5SWJqeEN0dHVaeExpbDdNcndlV2FpXzI5dXJTRWN6OHZ0ejJHMjh2REVaNTVWbUxTZlRiQm9ORk80RjBMOEdpZFk2Y2c3aXk3RV…
Cardiol Therapeutics Inc (CRDL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5pejZPOWp3QkE3bW5FMU1GZzVjUlE4UnhEOTluY1otTmxDVWt2bHpQTEV4anZfc1NuSVZ3WEJyY3Q2dW1MOUJrYnl6TjdsWGFfMjExX2Joa2NfbDZNRndfTDRBNkRQVEU?oc=5" target="_blank">Cardiol Therapeutics Inc (CR…
Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPdnNXYWJWU3pGMzV1OG5nSEZWN1FURjNIOWlmY2RDNjFzajl3TlRHYUtQRWVvZkxFYW9HcldRUUFtZmtzRlNNOEk5RlZ0UUU1V2lTSXRpc2Rrb1RQVUhKVWpLYnhwRHFqbDNiWlZUZlZwZ08xMzJzNGYyMG9WUE16N2p2VGZGNjRqeTV0cj…
CRDL — Frequently Asked Questions
What is the current share price of Cardiol Therapeutics Inc. (CRDL)?
As of 2026-09-19 21:16 PDT, Cardiol Therapeutics Inc. (CRDL) trades at $2.22 on NasdaqCM. Its 52-week range is $0.93 to $2.22.
What is the market capitalisation of CRDL?
Cardiol Therapeutics Inc. (CRDL) has a market capitalisation of $259.35M on NasdaqCM.
What is the P/E ratio of CRDL?
CRDL trades at a trailing price-to-earnings (P/E) ratio of -8.88. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 15.28.
Is CRDL a good stock to buy?
This page provides a data-driven analysis of Cardiol Therapeutics Inc. (CRDL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.